TAF1 inhibitor Bay-299 induces cell death in acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) is one of the most common hematopoietic malignancies. The cure rate of currently intensive chemotherapy in AML was only 40% or less, and there is an urgent need to develop novel effective therapeutic targets or drugs. The TATA-box binding protein associated f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Lixin, Yao, Qi, Ma, Le, Li, Hui, Chen, Jieping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798726/
https://www.ncbi.nlm.nih.gov/pubmed/35116379
http://dx.doi.org/10.21037/tcr-21-2295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798726/
https://www.ncbi.nlm.nih.gov/pubmed/35116379
http://dx.doi.org/10.21037/tcr-21-2295

Ejemplares similares